Oh, aspirin prophylaxis study: 1% lower mortality [p=0.95] and 12% fewer cases [p=0.04] https://c19p.org/oh2
copied to clipboard
Incidence and Mortality Associated with Cardiovascular Medication among Hypertensive COVID-19 Patients in South Korea
et al., Yonsei Medical Journal, doi:10.3349/ymj.2021.62.7.577
Retrospective database analysis of 328,374 adults in South Korea, showing lower risk of COVID-19 cases with aspirin use, but no difference in mortality for COVID-19 patients.
|
risk of death, 1.0% lower, OR 0.99, p = 0.95, adjusted per study, multivariable, RR approximated with OR.
|
|
risk of case, 12.0% lower, RR 0.88, p = 0.04, adjusted per study, odds ratio converted to relative risk, multivariable, control prevalance approximated with overall prevalence.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Oh et al., 17 Jun 2021, retrospective, database analysis, South Korea, peer-reviewed, 4 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.